Latest Regulatory News

Boab Metals has secured a A$236 million syndicated loan and final regulatory approvals, accelerating construction at its Sorby Hills Silver-Lead-Zinc Project with production on track for H2 2027.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Sierra Nevada Gold (ASX: SNX) advances its As Safra copper-gold project in Saudi Arabia by establishing a local subsidiary and preparing for imminent drilling after securing exploration licences.

Riedel Resources has confirmed high-grade gold and silver at its Kingman Project with new drilling results and advanced exploration plans, while moving to acquire controlling interests in two large Western Australian gold projects backed by a $2.5 million equity raise.

Saturn Metals has pressed forward with its Apollo Hill Gold Project, appointing Ausenco for the Definitive Feasibility Study and uncovering significant high-grade gold in the emerging Titan Zone, underpinning resource growth potential.

Finder Energy has secured A$27 million via a two-tranche placement plus a A$3 million share purchase plan to fast-track its KTJ oil project in Timor-Leste, aiming for final investment decision by mid-2026 and first oil by late 2027.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Electro Optic Systems (ASX: EOS) reported a 13% increase in contract backlog to A$518 million in Q1 2026, driven by multiple major defence orders and the opening of a new Singapore facility. The company’s cash position remains strong despite a $4 million ASIC penalty.

TG Metals reports exceptional metallurgical results from heap leach testwork on Laterite gold at Van Uden, unlocking a potential low-cost, near-term cashflow opportunity from over one million tonnes of surface material.